论文部分内容阅读
目的:探讨CDX2基因在急性髓细胞白血病(AML)患者的表达及临床意义。方法:初发AML患者66例,采用RT-PCR方法检测CDX2基因的表达,观察该基因表达与初治患者治疗效果的关系。结果:66例AML患者中,CDX2基因阳性表达56例,阳性率84.8%。51例非M3型AML患者中,CDX2表达阳性与阴性的完全缓解(CR)率分别为81.8%和71.4%,两者比较差异无统计学意义,P=0.896。对表达阳性的13例AML患者治疗后CDX2基因表达行动态观察,当获得CR时,CDX2表达可转阴性,复发时转为阳性,持续阳性者可早期复发;未获CR者可持续表达阳性。结论:CDX2基因在AML患者中有较高的表达。CDX2基因表达是否阳性对非M3型AML治疗CR率无影响。监测CDX2基因表达变化可作为检测微小残留病的有效手段。
Objective: To investigate the expression of CDX2 gene in patients with acute myeloid leukemia (AML) and its clinical significance. Methods: Sixty-six patients with newly diagnosed AML were recruited. The expression of CDX2 gene was detected by RT-PCR and the relationship between the expression of CDX2 gene and the therapeutic effect of the newly diagnosed patients was observed. Results: Among 66 cases of AML, 56 cases were positive for CDX2 gene, the positive rate was 84.8%. Among 51 non-M3 AML patients, the complete remission (CR) rates of positive and negative CDX2 were 81.8% and 71.4%, respectively, with no significant difference (P = 0.896). The expression of CDX2 gene in 13 AML patients with positive expression was dynamically observed. When CR was obtained, the expression of CDX2 turned negative, and turned to positive when it got CR. The positive expression of CDX2 was not found in those with persistent CR. Conclusion: The CDX2 gene is highly expressed in AML patients. Whether CDX2 gene expression is positive has no effect on the CR rate of non-M3 AML treatment. Monitoring CDX2 gene expression changes can be used as an effective means of detecting minimal residual disease.